Methylamine

Methylamine

SCHEMBL20788005

CCCCCCCCCCCCCC(=O)CC(C)C(=O)CCCCCCCCCCCCC.CN.CN

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CES2 O00748 4/20 0.50
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
FAAH O00519 1/20 0.47
MAPK1 P28482 1/20 0.47
MAPT P10636 1/20 0.47
CES1 P23141 3/20 0.43
LMNA P02545 1/20 0.43
HAO1 Q9UJM8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2992800 0.96 CES2 (0.53) CES2KMT2AMEN1FAAHMAPK1
SCHEMBL2999996 0.96 CES2 (0.53) CES2KMT2AMEN1FAAHMAPK1
SCHEMBL15188717 0.96 CES2 (0.53) CES2KMT2AMEN1FAAHMAPK1
SCHEMBL29770831 0.96 CES2 (0.53) CES2KMT2AMEN1FAAHMAPK1
Trimethylammonium SCHEMBL466595 0.91 CES2 (0.48) CES2KMT2AMEN1FAAHMAPK1
Trimethylammonium SCHEMBL467213 0.91 CES2 (0.48) CES2KMT2AMEN1FAAHMAPK1
Trimethylammonium SCHEMBL466946 0.91 CES2 (0.48) CES2KMT2AMEN1FAAHMAPK1
Dimethylamine SCHEMBL20788003 0.91 KMT2A (0.50) CES2KMT2AMEN1FAAHMAPK1
Dimethylamine SCHEMBL20788004 0.91 KMT2A (0.50) CES2KMT2AMEN1FAAHMAPK1
Trimethylammonium SCHEMBL29000430 0.91 CES2 (0.48) CES2KMT2AMEN1FAAHMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3456714-B1 BIODEGRADABLE COMPOUND, LIPID PARTICLE, COMPOSITION CONTAINING LIPID PARTICLE AND KIT TOSHIBA KK (JP) 2023-11-15 EP claimed
US-10639279-B2 Biodegradable compound, lipid particle, composition containing lipid particle, and kit KABUSHIKI KAISHA TOSHIBA (JP) 2020-05-05 US claimed
EP-3456714-A1 BIODEGRADABLE COMPOUND, LIPID PARTICLE, COMPOSITION CONTAINING LIPID PARTICLE AND KIT KABUSHIKI KAISHA TOSHIBA (JP) 2019-03-20 EP claimed
US-20190076358-A1 BIODEGRADABLE COMPOUND, LIPID PARTICLE, COMPOSITION CONTAINING LIPID PARTICLE, AND KIT KABUSHIKI KAISHA TOSHIBA (JP) 2019-03-14 US claimed
EP-3456714-B1 BIODEGRADABLE COMPOUND, LIPID PARTICLE, COMPOSITION CONTAINING LIPID PARTICLE AND KIT TOSHIBA KK (JP) 2023-11-15 EP disclosed
US-10639279-B2 Biodegradable compound, lipid particle, composition containing lipid particle, and kit KABUSHIKI KAISHA TOSHIBA (JP) 2020-05-05 US disclosed
EP-3456714-A1 BIODEGRADABLE COMPOUND, LIPID PARTICLE, COMPOSITION CONTAINING LIPID PARTICLE AND KIT KABUSHIKI KAISHA TOSHIBA (JP) 2019-03-20 EP disclosed
US-20190076358-A1 BIODEGRADABLE COMPOUND, LIPID PARTICLE, COMPOSITION CONTAINING LIPID PARTICLE, AND KIT KABUSHIKI KAISHA TOSHIBA (JP) 2019-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190076358-A1 BIODEGRADABLE COMPOUND, LIPID PARTICLE, COMPOSITION CONTAINING LIPID PARTICLE, AND KIT ACSL4, KIT, LIPC CES2 573/4885KMT2A 904/4885MEN1 2379/4885
US-10639279-B2 Biodegradable compound, lipid particle, composition containing lipid particle, and kit ACSL4, KIT, CCKAR CES2 644/4885KMT2A 1011/4885MEN1 2621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.